Company is expanding at three production sites over the next three years.
Boehringer Ingelheim (BI) will be investing 1.6 billion Mexican pesos ($84 million) by 2023 to expand capacity at all three of its manufacturing locations in Mexico. This investment is in line with the company’s strategy to develop and manufacture more complex tablets for global launches at the $100 million R&D and manufacturing facility currently under construction in Germany and move its “older, easier-to-manufacture drugs” to other plants around the globe.
Of the 1.6 billion pesos to be spent in Mexico, 1 billion ($52 million) will be invested in the company’s site in Xochimilco, which produces diabetes medications. The investment, which will be made over the next two years, will be used to expand capacity and enable BI to increase exports to the United States and various Central and South American countries. BI’s goal is to eventually reach 2.5 billion tablets per year by 2028 at this facility (up from 1.6 billion today).